Legend Biotech is a biopharmaceutical company developing cell-based cancer treatments across the United States, China, and Europe. Its primary focus is ciltacabtagene autoleucel (cilta-cel), a CAR-T cell therapy approved for multiple myeloma, alongside a pipeline of earlier-stage CAR-T candidates targeting various malignancies and investigational allogeneic cell therapies. The company operates through partnerships with Janssen Biotech for cilta-cel commercialization and with Novartis for development of additional CAR-T therapies.

entry readiness 39 · WEAK SETUP · exit proximity 0

Value area 16.86–25.53 · 98% of 120d volume overhead · heavy supply